Skip to main content

Table 3 Clinical outcomes by subgroup analysis

From: Impact of vitamin D supplementation on the clinical outcomes of COVID-19 pneumonia patients: a single-center randomized controlled trial

Any type of oxygen support

Intervention group

(n = 61)

Control group

(n = 56)

P-value

    Pneumonia treatment duration, days, median (IQR)

9.00 (8.50)

9.00 (7.75)

0.835

    Length of hospital stay, days, median (IQR)

12.00 (8.50)

11.00 (9.50)

0.893

    PSI, median (IQR)

    PSI at enrollment

56.00 (32.50)

61.00 (39.00)

0.261

    PSI at discharge

52.00 (30.50)

60.00 (34.75)

0.028*

    P-value

 < 0.001*

0.803

 

    PSI reduction from baseline

P-value 0.030*

Enrollment 25OHD < 12 ng/mL

Intervention group

(n = 7)

Control group

(n = 6)

P-value

    Pneumonia treatment duration, days, median (IQR)

10.00 (17.00)

12.50 (14.75)

0.836

    Length of hospital stay, days, median (IQR)

13.00 (17.00)

17.00 (18.00)

0.836

    PSI, median (IQR)

    PSI at enrollment

57.00 (48.00)

69.00 (44.75)

0.534

    PSI at discharge

43.00 (34.00)

68.50 (40.50)

0.101

    P-value

0.059

0.317

 

    PSI change from baseline

**

Enrollment 25OHD < 20 ng/mL

Intervention group

(n = 44)

Control group

(n = 33)

P-value

    Pneumonia treatment duration, days, median (IQR)

7.00 (9.50)

8.00 (4.50)

0.737

    Length of hospital stay, days, median (IQR)

9.00 (10.50)

9.00 (5.00)

0.602

    PSI, median (IQR)

    PSI at enrollment

40.50 (37.00)

56.00 (30.50)

0.024*

    PSI at discharge

37.50 (32.50)

45.00 (35.50)

0.034*

    P-value

0.023

0.056

 

    PSI change from baseline

P-value 0.799

Prednisolone dose ≥ 1 mg/kg/day

Intervention group

(n = 39)

Control group

(n = 46)

P-value

    Pneumonia treatment duration, days, median (IQR)

9.00 (8.00)

9.00 (6.50)

0.114

    Length of hospital stay, days, median (IQR)

13.00 (9.00)

10.50 (7.00)

0.068

    PSI, median (IQR)

    PSI at enrollment

57.00 (29.00)

60.00 (32.50)

0.537

    PSI at discharge

56.00 (28.00)

60.00 (33.25)

0.075

    P-value

0.008*

0.882

 

    PSI change from baseline

P-value 0.060

Lymphopenia (ALC < 1000 cells/mm3)

Intervention group

(n = 33)

Control group

(n = 34)

P-value

    Pneumonia treatment duration, days, median (IQR)

6.00 (5.00)

7.00 (4.25)

0.138

    Length of hospital stay, days, median (IQR)

7.00 (8.50)

8.00 (5.00)

0.317

    PSI, median (IQR)

    PSI at enrollment

58.00 (36.50)

57.50 (35.75)

0.494

    PSI at discharge

56.00 (33.50)

51.00 (41.75)

0.940

    P-value

0.050

0.784

 

    PSI change from baseline

P-value 0.120

  1. ALC absolute lymphocyte count, IQR interquartile range, PSI pneumonia severity index, 25OHD 25-hydroxyvitamin D
  2. *p-value < 0.05
  3. **unable to determine p-value owing to small sample size
Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us